Caricamento...
Building a CAR Garage: Preparing for the delivery of commercial CAR T products at Memorial Sloan Kettering Cancer Center.
Two commercial Chimeric Antigen Receptor (CAR) T cell therapies for CD19 expressing B cell malignancies, Kymriah and Yescarta, have recently been approved by the FDA. The administration of CAR T cells is a complex endeavor involving cell manufacture, tracking and shipping of apheresis products, and...
Salvato in:
| Pubblicato in: | Biol Blood Marrow Transplant |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6625528/ https://ncbi.nlm.nih.gov/pubmed/29499327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2018.02.018 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|